EIF2AK1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL869349	0.79	6/20
SCHEMBL868814	1.00	5/20
SCHEMBL870782	1.00	5/20
SCHEMBL869008	0.86	5/20
SCHEMBL870161	0.84	5/20
SCHEMBL869311	0.84	5/20
SCHEMBL869038	0.80	5/20
SCHEMBL868723	0.79	5/20
SCHEMBL869024	0.79	5/20
SCHEMBL869035	0.78	5/20
SCHEMBL869344	0.77	5/20
SCHEMBL868275	0.77	5/20
SCHEMBL869020	0.75	5/20
SCHEMBL868281	0.74	5/20
SCHEMBL869359	0.73	5/20
SCHEMBL868357	0.70	5/20
SCHEMBL868696	0.70	5/20
SCHEMBL868264	0.64	5/20
SCHEMBL869170	0.63	5/20
SCHEMBL868854	0.62	5/20

Clinical trials — most relevant to EIF2AK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes	PHASE4	UNKNOWN
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit	PHASE2/PHASE3	WITHDRAWN
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer	PHASE1/PHASE2	COMPLETED
Tianasen (ASO-GNAO1) for GNAO1-Encephalopathy With Epilepsy and Movement Disorders.	PHASE1/PHASE2	RECRUITING
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery	PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity	PHASE2	RECRUITING
Targeting Endoplasmic Reticulum Stress in Human Hypertension	PHASE1/PHASE2	RECRUITING
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant	PHASE1/PHASE2	RECRUITING
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment	PHASE1	COMPLETED
Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer	PHASE1	COMPLETED
PBA Use for Treatment of ATF6-/- Patients	EARLY_PHASE1	SUSPENDED
Quantification of GADD34 Expression in RA	nan	COMPLETED
MEHMO Natural History and Biomarkers	nan	RECRUITING
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory	nan	COMPLETED
The Effects of Whey vs. Collagen on MPS	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
Testing of Micellar Casein, Blended Micellar Casein and Native Whey	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Effect of Protein on Endoplasmic Reticulum Stress	nan	NOT_YET_RECRUITING
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy	nan	RECRUITING
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
Generating Intervals of Reference FFor Early Life Brain Biomarkers.	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a EIF2AK1 binder may also engage these)

Protein	Name	Similarity
Q4R8E0	—	1.000	Q4R8E0 →
Q9Z2R9	—	1.000	Q9Z2R9 →
P33279	—	1.000	P33279 →
Q63185	—	0.997	Q63185 →
Q8BMD7	—	0.997	Q8BMD7 →
Q6IVY4	—	0.997	Q6IVY4 →
Q6YY75	—	0.997	Q6YY75 →
Q9FY74	—	0.996	Q9FY74 →
Q9DDT2	—	0.996	Q9DDT2 →
A7MBB4	—	0.995	A7MBB4 →
F4JZ68	—	0.995	F4JZ68 →
Q9LSP8	—	0.995	Q9LSP8 →
A7YDW0	—	0.994	A7YDW0 →
BRPF3	Bromodomain and PHD finger-containing protein 3	0.993	landscape →
Q8AXC7	—	0.993	Q8AXC7 →
Q80TM9	—	0.993	Q80TM9 →
Q8BZ21	—	0.993	Q8BZ21 →
Q8CDA1	—	0.993	Q8CDA1 →
Q9FT70	—	0.993	Q9FT70 →
Q9UTE5	—	0.993	Q9UTE5 →
Q8N2I9	—	0.993	Q8N2I9 →
Q7T0B1	—	0.993	Q7T0B1 →
P25799	—	0.993	P25799 →
Q6DD45	—	0.993	Q6DD45 →
Q5XIK8	—	0.993	Q5XIK8 →
Q9AWM8	—	0.993	Q9AWM8 →
KAT6B	Histone acetyltransferase KAT6B	0.992	landscape →
O35607	—	0.992	O35607 →
Q9GKT0	—	0.992	Q9GKT0 →
NEK3	Serine/threonine-protein kinase Nek3	0.992	landscape →